Zhang Financial LLC Sells 4,818 Shares of Pfizer Inc. $PFE

Zhang Financial LLC trimmed its stake in Pfizer Inc. (NYSE:PFE) by 17.9% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 22,040 shares of the biopharmaceutical company’s stock after selling 4,818 shares during the quarter. Zhang Financial LLC’s holdings in Pfizer were worth $534,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of PFE. Pacer Advisors Inc. lifted its position in shares of Pfizer by 856.8% in the first quarter. Pacer Advisors Inc. now owns 20,053,828 shares of the biopharmaceutical company’s stock valued at $508,164,000 after buying an additional 17,957,928 shares during the last quarter. Amundi lifted its position in shares of Pfizer by 43.4% in the first quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company’s stock valued at $1,265,277,000 after buying an additional 15,758,846 shares during the last quarter. Nuveen LLC acquired a new stake in shares of Pfizer in the first quarter valued at approximately $389,861,000. Goldman Sachs Group Inc. lifted its position in shares of Pfizer by 51.9% in the first quarter. Goldman Sachs Group Inc. now owns 26,456,457 shares of the biopharmaceutical company’s stock valued at $670,407,000 after buying an additional 9,041,990 shares during the last quarter. Finally, Vanguard Group Inc. lifted its position in shares of Pfizer by 0.9% in the first quarter. Vanguard Group Inc. now owns 523,165,127 shares of the biopharmaceutical company’s stock valued at $13,257,004,000 after buying an additional 4,629,976 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

PFE has been the subject of a number of recent analyst reports. Bank of America raised their price objective on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research report on Friday, October 3rd. UBS Group reaffirmed a “neutral” rating and issued a $28.00 price objective on shares of Pfizer in a research report on Wednesday, October 1st. Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Morgan Stanley dropped their price target on Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a report on Friday, October 10th. Finally, Citigroup lifted their price target on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $28.13.

Pfizer Price Performance

Shares of NYSE PFE opened at $24.53 on Wednesday. The stock has a market capitalization of $139.44 billion, a PE ratio of 13.05, a P/E/G ratio of 0.82 and a beta of 0.55. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The business has a fifty day moving average price of $24.84 and a two-hundred day moving average price of $24.23. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $29.17.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.58 by $0.20. The firm had revenue of $14.65 billion during the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, November 7th. This represents a $1.72 annualized dividend and a yield of 7.0%. Pfizer’s payout ratio is currently 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.